Navigation Links
Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Date:9/20/2011

HOBOKEN, N.J. and PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

NKP-1339 Phase I Interim DataThe Phase I trial is conducted in patients with metastatic solid tumors resistant to standard therapies. Previous to enrollment in the trial, all patients had received multiple standard therapies and exhibited disease progression on their last treatment. Of the first 24 patients enrolled, six patients (25%) exhibited anti-tumor activity, demonstrated by disease stability and/or tumor regression for at least 12 weeks.

Of the responding six patients, one patient with carcinoid tumor, a non-pancreatic neuroendocrine tumor (non-pNET), has tumor regression and continues on NKP-1339 therapy for more than 70 weeks. The five other patients have experienced stable disease of up to 24 weeks with NKP-1339 treatment. These patients have the following tumor types: one gastrinoma non-pNET, one colorectal cancer, two non-small cell lung cancers and one cancer of unknown primary.

NKP-1339 treatment has been well tolerated to date with mild manageable side effects. The most common drug-related side effects are grade 1-2 fever and mild flu-like symptoms, which can be prevented with standard medications. The maximum tolerated dose has not been reached and NKP-1339 dose escalation continues.

The trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute (TGen), and Dr. Howard Burris, Director of Drug Development at the Sarah Cannon Research Institute (SCRI).

"We need new treatments for patients with non-pNET. The NKP-1339 anti-tumor activity observed in these two non-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
3. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
6. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
7. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
8. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
9. Pharmasset to Present at Two Upcoming Conferences
10. MDC Partners Launches Integrated Healthcare Marketing Platform With Acquisition of Majority Stake in Concentric Pharma Advertising
11. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 23D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Ga., April 16, 2012  GeckoSystems Intl. Corp. (Pink ... ) -- is closely reviewing the scope and ... wheelchair technology. As a result of recent enhancements ... suite of fundamental mobile robot solutions for automatic, ...
... 16, 2012  Morphotek®, Inc., a subsidiary of Eisai Inc., ... II study evaluating the safety and efficacy of MORAb-004 ... refractory to all standard therapy. MORAb-004 is a monoclonal ... The trial is a randomized, double-blind, ...
Cached Medicine Technology:GeckoSystems Evaluates Europe's Robotic Wheelchair Market 2GeckoSystems Evaluates Europe's Robotic Wheelchair Market 3GeckoSystems Evaluates Europe's Robotic Wheelchair Market 4GeckoSystems Evaluates Europe's Robotic Wheelchair Market 5GeckoSystems Evaluates Europe's Robotic Wheelchair Market 6Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 3
(Date:7/31/2015)... York, New York (PRWEB) , ... July 31, 2015 , ... ... to strut their stuff, Super-Sod debuted their new type of sod called Leisure ... registered trademark application in process. , To commemorate introduction of this new type of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 , ... ... Pet Sitter believes community involvement and support of animal welfare organizations is essential to ... for the third consecutive year in the National Association of Professional Pet Sitters (NAPPS) ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4
... Assisted Living At Home ... extensive ratings and reviews. Finding a quality retirement community ... resources out there dedicated to assisting families to make the right ... information is compounded by the fact that most people do not ...
... plans offer lower premiums, greater peace of mind , ... the region are finding themselves in a serious predicament: less ... jobs have received employment offers, according to the National Association ... health insurance. , , As a result, many ...
... repair damaged cardiac muscle, surgeons say , TUESDAY, June 30 ... procedure in which a patient received injections of his own ... 39-year-old man is the first of 16 people who will ... trial being conducted at Cedars-Sinai Heart Institute in Los Angeles. ...
... concern is that the drug can cause liver damage, even ... -- U.S. health advisers recommended Tuesday to lower the maximum ... Excedrin and many other pain-killing medications. , The advisers, vote ... report last month. It found that severe liver damage and ...
... women , TUESDAY, June 30 (HealthDay News) -- ... components of metabolic syndrome might be at increased risk ... Metabolic syndrome, also known as insulin resistance syndrome, consists ... high blood glucose levels, impaired glucose tolerance, abnormal lipid ...
... With his legacy in the balance, Governor urged to sign ... With just 12 hours left until California begins to default ... small businesses, health care workers and community activists are gathering ... that Governor Schwarzenegger stop blocking a compromise budget package that ...
Cached Medicine News:Health News:New Assisted Living at Home (assistedlivingathome.com) Database Locates Ideal Retirement Communities for Your Loved One 2Health News:Graduates Needing Health Insurance Have Cost-Effective Options 2Health News:Graduates Needing Health Insurance Have Cost-Effective Options 3Health News:U.S. Doctors Treat Heart Attack With Man's Own Stem Cells 2Health News:FDA Advisers Urge Smaller Doses of Acetaminophen 2Health News:FDA Advisers Urge Smaller Doses of Acetaminophen 3Health News:Metabolic Syndrome May Make Breast Cancer More Likely 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: